ORIC starts Phase 3 Himalayas-1 of rinzimetostat with Bayer's darolutamide in mCRPC
The company reported third-quarter 2026 results as it launched a global Phase 3 trial in post-abiraterone metastatic castration-resistant prostate cancer, following End-of-Phase 1 talks with regulators.
ORIC Pharmaceuticals said on 16 November 2026 that it has started Himalayas-1, a global Phase 3 trial of rinzimetostat combined with Bayer's darolutamide in metastatic castration-resistant prostate cancer (mCRPC) after prior abiraterone treatment. The announcement came alongside the company's third-quarter 2026 financial results.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Oric Pharmaceuticals, Inc. ↗
Article written by VigiEye from the official source (Oric Pharmaceuticals, Inc.). Claims are the company's own. AI-assisted; check the source before acting.